CStone Submits Application to the European Medicines Agency for New Indication of Sugemalimab in Stage III Non-Small Cell Lung Cancer

[
CStone Submits Application to the European Medicines Agency for New Indication of Sugemalimab in Stage III Non-Small Cell Lung Cancer
[og_img]
https://www.investing.com/news/press-releases/cstone-submits-application-to-the-european-medicines-agency-for-new-indication-of-sugemalimab-in-stage-iii-nonsmall-cell-lung-cancer-93CH-3943449


Investing.com